Mitochondrial NADP(H)–dependent de novo dTMP biosynthesis counteracts the cytotoxicity of PARP inhibitors
Open Access
- 24 September 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Abstract
PARP inhibitors (PARPis), known to elicit mitochondrial protection in nononcological diseases by elevating the cellular NAD + pool, exhibit potent cytotoxicity in selected human cancers. The role of mitochondrial metabolism in PARPi-mediated antitumor therapy remains unexplored. Here, we propose a causal link between mitochondrial NAD + metabolism and PARPi responsiveness. In PARPi-non-responsive tumor cells, PARP inhibition specifically expands mitochondrial NADP(H) [mito-NADP(H)] pool, thereby facilitating de novo mitochondrial dTMP (mito-dTMP) biosynthesis and maintaining mitochondrial dTTP (mito-dTTP) pool to prevent uracil misincorporation into mitochondrial DNA (mtDNA), regardless of homologous recombination (HR) status. Mechanistically, loss of PTPN1 ADPRylation by PARPi abolishes its phosphatase activity toward STAT3, yielding enhanced STAT3 phosphorylation and the subsequent transactivation of FoxO1. FoxO1 modulates transcriptomic signature governing mitochondrial NADPH fluxes to de novo mito-dTMP generation. Our results uncover a fundamental vulnerability that can be leveraged by cotargeting STAT3 and PARP to trigger mitochondrial dysfunction.Keywords
Funding Information
- National Natural Science Foundation of China (82530096)
- National Natural Science Foundation of China (82330089)
- National Natural Science Foundation of China (U2005203)
- National Natural Science Foundation of China (81725012)
- Special Research Fund for Clinical Studies of Innovative Drugs after Market Launch (WKZX2023CX110001)
- Peking University (PY202332)
This publication has 64 references indexed in Scilit:
- Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialAnnals of Oncology, 2023
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian CancerJAMA Oncology, 2023
- Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialAnnals of Oncology, 2023
- Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsJAMA Oncology, 2021
- Deoxynucleoside Therapy for Thymidine Kinase 2–Deficient MyopathyAnnals of Neurology, 2019
- Olaparib Tablet: A Review in Ovarian Cancer Maintenance TherapyTargeted Oncology, 2018
- Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 DeficiencyAnnals of Neurology, 2017
- Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for CancerCancer Cell, 2016
- Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic OptionsNeurotherapeutics, 2013
- Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cellsEMBO Molecular Medicine, 2012